Angiogenesis and anti-angiogenesis in hepatocellular carcinoma

Cancer Treatment Reviews

Volumn 32, Issue 6, 2006, Pages 437-444

  Ribatti, Domenico ^a   Vacca, Angelo ^a   Nico, Beatrice ^a   Sansonno, Domenico ^a   Dammacco, Franco ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; Anti angiogenesis; Hepatocellular carcinoma; Tumor progression

Indexed keywords

ALCOHOL; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BATIMASTAT; BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; ENDOSTATIN; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GEMCITABINE; INTERLEUKIN 12; IRINOTECAN; MATRIX METALLOPROTEINASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA2B INTERFERON; THALIDOMIDE; THROMBOSPONDIN 1; VATALANIB; ZK 22254;

ANTIANGIOGENIC ACTIVITY; CANCER GROWTH; CLINICAL ASSESSMENT; CLINICAL STUDY; CLINICAL TRIAL; HUMAN; LIVER CELL CARCINOMA; MICROVASCULARIZATION; NONHUMAN; PROGNOSIS; REVIEW; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS; HUMANS; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33748147734     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.06.002     Document Type: Review

References (86)

1. Ribatti D., Vacca A., and Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1 (1999) 293-302
2. Mignatti P., and Rifkin D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73 (1993) 161-195
3. Aznavoorian S., Murphy A.N., Stetler-Stevenson W.G., and Liotta L.A. Molecular aspects of tumor cell invasion. Cancer 71 (1993) 1368-1383
4. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
5. Mc Cuskey R.S., and Reilly F. Hepatic microvasculature: dynamic structure and its regulation. Sem Liver Dis 13 (1993) 1-12
6. Mc Cuskey R.S. The hepatic microvascular system. In: Arias I.M., Boyer J.L., Fausto N., Jakoby W.B., Schachter D.A., and Shafritz D.A. (Eds). The liver: biology and pathology (1994), Raven Press, New York 1089-1106
7. Camenisch G., Pisabarro M., Sherman D., et al. ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha v beta 3 and induces blood vessel formation in vivo. J Biol Chem 227 (2002) 17281-17290
8. Nakashima T., and Kojiro M. Angioarchitecture of hepatocellular carcinoma. Hepatocellular carcinoma: an atlas of its pathology (1987), Springer Verlag, Tokyo 105-115
9. Maeda T., Adachi E., Kajiyama K., et al. CD34 expression in endothelial cells of small hepatocellular carcinoma: its correlation with tumour progression and angiographic findings. J Gastroenterol Hepatol 10 (1995) 650-654
10. Sonoda T., Shirabe K., Takenaka K., Kanematsu T., Yasumori K., and Sugimachi K. Angiographically undetected small hepatocellular carcinoma: clinicopathological characteristics, follow-up and treatment. Hepatology 10 (1989) 1003-1007
11. Sakamoto M., Ino Y., Fujii T., and Hirohashi S. Phenotype changes in tumor vessels associated with the progression of hepatocellular carcinoma. Jpn Clin Oncol 23 (1993) 98-104
12. Haratake J., and Scheuer P.J. An immunohistochemical and ultrastructural study of the sinusoids of hepatocellular carcinoma. Cancer 65 (1990) 1985-1993
13. Mochida S., Ishikawa K., Toshima K., et al. The mechanisms of hepatic sinusoidal endothelial cell regeneration: a possible communication system associated with vascular endothelial growth factor in liver cells. J Gastroenterol Hepatol 13S (1998) S1-S5
14. Yamane A., Seetharam L., Yamaguchi S., et al. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene 9 (1994) 2683-2690
15. De Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., and Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255 (1992) 989-991
16. Quinn T.P., Peters K.G., De Vries C., Ferrara N., and Williams L.T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 90 (1993) 7533-7537
17. Le Couter J., Moritz D., Li B., et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299 (2003) 890-893
18. Yamaguchi R., Yano H., Iemura A., Ogasawara S., Haramaki M., and Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28 (1998) 68-77
19. Mise M., Arii S., Higashituji H., et al. Clinical significance of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hepatology 23 (1996) 455-464
20. Chow N.H., Hsu P.I., Lin X.Z., et al. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 28 (1997) 698-703
21. Park Y.N., Kim Y.B., Yang K.M., and Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 124 (2000) 1061-1065
22. Poon R.T., Lau C.P., Cheung S.T., Yu W.C., and Fan S.T. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 63 (2003) 3121-3126
23. Jinno K., Tanimizu M., Hyodo I., et al. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 33 (1998) 376-382
24. Chao Y., Li C.P., Chau G.Y., et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10 (2003) 355-362
25. Poon R., Lau C., Yu W., Fan S., and Wong J. High serum level of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 11 (2004) 1077-1084
26. von Marschall Z., Cramer T., Hocker M., Finkenzeller G., Wiedenmann B., and Rosewicz S. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 48 (2001) 87-96
27. El-Assal O.N., Yamanoi A., Ono T., Kohno H., and Nagasue N. The clinicopathological significance of heparanase and basic fibroblast growth factor expression in hepatocellular carcinoma. Clin Cancer Res 7 (2001) 1299-1305
28. Poon R.T., Hg I.O., Lau C., Yu W.C., Fan S.T., and Wong J. Correlation of serum basic fibroblast growth factor levels with clinicopathological features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 182 (2001) 298-304
29. Hisai H., Kato J., Kobune M., et al. Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin Cancer Res 9 (2003) 4849-4852
30. Tanaka S., Mori M., Sakamoto Y., Makuuchi M., Sugimachi K., and Wands J.R. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103 (1999) 341-345
31. Mitsuhashi N., Shimizu H., Ohtsuka M., et al. Angiopoietin and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 37 (2003) 1105-1113
32. Sugimachi K., Tanaka S., Terashi T., Taguchi K., and Rikimaru T. The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumor progression. Surgery 131 (2002) S135-S141
33. Chen L., Yang Z., Wang G., and Wang C. Expression of angiopoietin-2 gene and its receptor Tie-2 in hepatocellular carcinoma. J Tongji Med Univ 21 (2001) 228-230
34. Peng S.H., Deng H., Yang J.F., et al. Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues. World J Gastroenterol 11 (2005) 6521-6524
35. Bingle L., Brown N.J., and Lewis C.E. The role of tumor associated macrophages in tumor progression: implications for new anticancer therapies. J Pathol 196 (2002) 254-265
36. Ribatti D., Crivellato E., Roccaro A.M., Ria R., and Vacca A. Mast cell contribution to angiogenesis related to tumor progression. Clin Exp Allergy 34 (2004) 1660-1664
37. Semenza G.L. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 7 (2001) 345-350
38. Moon E.J., Jeong C.H., Jeong J.W., et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor 1 alpha. FASEB J 18 (2004) 382-384
39. Kim J.H., Kim T.H., Jang J.W., et al. Analysis of matrix metalloproteinase mRNAs expressed in hepatocellular carcinoma cell lines. Mol Cells 12 (2001) 32-40
40. Monvoisin A., Bisson C., Si-Tayeb K., Balabaud C., Desmouliere A., and Rosenbaum J. Involvement of matrix metalloproteinase type-3 in hepatocyte growth factor-induced invasion of human hepatocellular carcinoma cells. Int J Cancer 97 (2002) 157-162
41. Giannelli G., Bergamini C., Fransvea E., Marinosci F., Quaranta V., and Antonaci S. Human hepatocellular carcinoma (HCC) cells require both alpha 3 beta 1 integrin and matrix metalloproteinase activity for migration and invasion. Lab Invest 81 (2001) 613-627
42. McMahon G., Vu T.H., Ito H.T., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2 (2000) 737-744
43. Dhar D.K., Ono T., Yamanoi A., et al. Serum endostatin predicts tumor vascularity in hepatocellular carcinoma. Cancer 95 (2002) 2188-2195
44. Hu T.H., Huang C.C., Wu C.L., et al. Increased endostatin/collagen XVIII expression correlates with elevated VEGF level and poor prognosis in hepatocellular carcinoma. Mod Pathol 18 (2005) 663-672
45. Ishikawa H., Nakao K., Matsumoto K., et al. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene. Hepatology 37 (2003) 696-704
46. Kawahara N., Ono M., Taguchi K., et al. Enhanced expression of thrombospondin-1 and hypovascularity in human choloangiocarcinoma. Hepatology 28 (1998) 1512-1517
47. Poon R.T., Chung K.K., Cheung S.T., et al. Clinical significance of thrombospondin-1 expression in hepatocellular carcinoma. Clin Cancer Res 10 (2004) 4150-4157
48. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med 285 (1971) 1182-1186
49. Wood J.M., Bold G., Buchdunger E., et al. PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth-factor-induced responses and tumor growth after oral administration. Cancer Res 60 (2000) 2178-2189
50. Liu Y., Poon R.T., Li Q., Kok T.W., Lau C., and Fan S. Both anti-angiogenesis and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK22584. Cancer Res 65 (2005) 3691-3699
51. Raskopf E., Dzienisowicz C., Hilbert T., et al. Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model. Hepatology 41 (2005) 1233-1240
52. Ranson M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer 90 (2004) 2250-2255
53. Matsuo M., Sakurai H., and Saiki I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther 2 (2003) 557-561
54. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57 (1997) 4539-4599
55. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
56. Schwartz JD, Schwartz M, Goldman J, et al. Bavacizumab in hepatocellular carcinoma in patients without invasion of the portal vein. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 2004;22(14S):4088.
57. Schwartz JD, Schwartz M, Lehrer D, et al. Bevacizumab in hepatocellular carcinoma (HCC) in patients without metastasis and without invasion of the portal vein. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 2005;23(16S):4122.
58. Zhu A.X., Blaszkowsky L.S., Ryan D.P., et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 1898-1903
59. Ribatti D., and Vacca A. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia 19 (2005) 1525-1531
60. Figg W.D., Raje S., Bauer S.K., et al. Pharmacokinetics of thalidomide in AIDS-related Kaposi's sarcoma. J Pharmacol Sci 88 (1999) 121-125
61. Fine H.A., Figg W.D., Jaeckle K., et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18 (2000) 708-715
62. Eisen T., Boschoff C., Mak I., et al. Continuous low dose thalidomide: phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82 (2000) 812-817
63. Hsu C., Chen C.N., Chen L.T., et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 65 (2003) 242-249
64. Wang T.E., Kao C.R., Lin S.C., et al. Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 10 (2004) 649-653
65. Lin A.Y., Brophy N., Fisher G.A., et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 103 (2005) 119-125
66. Patt Y.Z., Hassan M.M., Lozano R.E., et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a Phase II trial. Cancer 103 (2005) 749-755
67. Brouty-Boye D., and Zetter B.R. Inhibition of cell motility by interferon. Science 208 (1980) 516-518
68. Folkman J. Endogenous angiogenesis inhibitors. APMIS 112 (2004) 496-507
69. Wang L., Wu W.Z., Sun H.C., et al. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastroenterol Surg 7 (2003) 587-594
70. Shiratori Y., Shiina S., Teratani T., et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138 (2003) 299-306
71. Lin S.M., Lin C.J., Hsu C.W., et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 100 (2004) 376-382
72. Patt Y.Z., Hassan M.M., Lozano R.D., et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alpha-2b for treatment of hepatocellular carcinoma. J Clin Oncol 21 (2003) 421-427
73. Voest E.E., Kenyon B.M., O'Reilly M.S., Truitt G., D'Amato R.J., and Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87 (1995) 581-586
74. Sgadari C., Angiolillo A.L., and Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87 (1996) 3877-3882
75. Dias S., Boyd R., and Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 78 (1998) 361-365
76. Barajas M., Mazzolini G., Genove G., et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interelukin 12. Hepatology 33 (2001) 52-61
77. Peron J., Couderc B., Rochaix P., et al. Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12. J Gastroenterol Hepatol 19 (2004) 388-396
78. Kudelka A.P., Verschraegen C.F., and Loyer E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. New Engl J Med 338 (1998) 981-992
79. Stadler W.M., Kuzel T., Shapiro C., Sosman J., Clark J., and Vogelzang N.J. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 17 (1999) 2541-2545
80. Teicher B.A. Potentiation of cytotoxic cancer therapies by antiangiogenic agents. In: Teicher B.A. (Ed). Antiangiogenic Agents in Cancer Therapy (1999), Humana Press, Totowa 277-316
81. Kin M., Torimura T., Uen T., et al. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int J Oncol 16 (2000) 375-382
82. Bu W., Tang Z.Y., Sun F.X., et al. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepatogastroenterology 45 (1998) 1956-1961
83. Tai K.F., Chen P.J., Chen D.S., and Hwang L.H. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors. J Gene Med 5 (2003) 386-398
84. Chen C.T., Lin J., Li Q., et al. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vector expressing secretable endostatin. Hum Gene Ther 11 (2000) 1983-1996
85. Eder Jr. J.P., Supki J.G., Clark J.W., et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20 (2002) 3772-3784
86. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2 (2002) 727-739